Login
$GMED
$70.50 +$0.00 (0.0%) After hours

$GMED 8-K SEC Filings

Filed On Filing
05 Nov 2026 8-K: Results of Operations and Financial Condition; Other Events

AUDUBON, PA., November 5, 2026: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the third quarter ended September 30, 2026.

06 Aug 2026 8-K: Results of Operations and Financial Condition

AUDUBON, PA., August 6, 2026: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the second quarter ended June 30, 2026.

04 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

The purpose of the Globus Medical, Inc. 2021 Equity Incentive Plan (as it may be amended or restated from time to time, the “Plan”) is to promote the success and enhance the value of Globus Medical, Inc. (the “Company”) by linking the in...

07 May 2026 8-K: Results of Operations and Financial Condition

AUDUBON, PA., May 7, 2026: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the first quarter ended March 31, 2026.

23 Mar 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

AUDUBON, Pa., March 23, 2026 (GLOBE NEWSWIRE) — Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced that John A. DeFord, Ph.D., a Director of Globus Medical Inc., notified the company of his dec...

24 Feb 2026 8-K: Results of Operations and Financial Condition

AUDUBON, PA, February 24, 2026: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology solutions company, today announced its financial results for the fourth quarter and year ended December 31, 2025.

07 Jan 2026 8-K: Results of Operations and Financial Condition

AUDUBON, PA, January 7, 2026: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ended December 31, 2025. The company a...

06 Nov 2025 8-K: Results of Operations and Financial Condition

AUDUBON, PA, November 6, 2025: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2025.

07 Aug 2025 8-K: Results of Operations and Financial Condition

AUDUBON, PA, August 7, 2025: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2025.

21 Jul 2025 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more

AUDUBON, PA, July 21, 2025: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced that Keith Pfeil, Executive Vice President, Chief Operating Officer and Chief Financial Officer, has been appoin...

05 Jun 2025 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

(e)On June 4, 2025, Globus Medical, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) at which the Company’s stockholders approved the amendment to the 2021 Equity Incentive Plan (the “2021 Equity I...

15 May 2025 8-K: Other Events

AUDUBON, Pa. – May 15, 2025 (GLOBE NEWSWIRE) – Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced that its Board of Directors has authorized a share repurchase program of up to $500 million of...

08 May 2025 8-K: Results of Operations and Financial Condition

AUDUBON, PA, May 8, 2025: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2025.

03 Apr 2025 8-K: Completion of Acquisition or Disposition of Assets; Regulation FD Disclosure

AUDUBON, Pa., April 3, 2025 – Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it completed its previously announced acquisition of Nevro Corp., a global medical device company that is deli...

20 Feb 2025 8-K: Results of Operations and Financial Condition

AUDUBON, PA, February 20, 2025: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the fourth quarter and year ended December 31, 2024.

06 Feb 2025 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more

B – Certificate of Incorporation of the Surviving Corporation

08 Jan 2025 8-K: Results of Operations and Financial Condition

AUDUBON, PA, January 8, 2025: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ending December 31, 2024. The company ...

05 Nov 2024 8-K: Results of Operations and Financial Condition

AUDUBON, PA, November 5, 2024: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2024.

13 Aug 2024 8-K: Other Events

On July 16, 2024, Globus Medical, Inc. received a warning letter from the U.S. Food and Drug Administration (the “FDA”) following an inspection of our facilities in Audubon, Pennsylvania. In the warning letter, the FDA cited deficiencies...

06 Aug 2024 8-K: Results of Operations and Financial Condition

AUDUBON, PA, August 6, 2024: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2024.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support